Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
STAMFORD, Conn., May 02, 2018 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 9, 2018, at 4:30 p.m. ET to report first quarter 2018 financial results and provide a corporate update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 1264618. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Additionally, CR845/difelikefalin has demonstrated efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product, and its safety and efficacy have not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
[email protected]
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
[email protected]
